IPC Classes  ?

• C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
• C12N 1/06 - Lysis of microorganisms
• C12N 1/20 - BacteriaCulture media therefor
• C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/475 - Growth factorsGrowth regulators
• C12N 5/074 - Adult stem cells
• C12N 15/867 - Retroviral vectors
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

Methods and systems for tracing an elongate object in image data are disclosed. The methods and systems may be operative for, e.g., neurite tracing. An artificial intelligence model is used to infer a steering prediction. The steering prediction is processed to determine a next one of a series of points (60) on a center line (50) of the elongate object.

IPC Classes  ?

• G06T 3/60 - Rotation of whole images or parts thereof
• G06T 7/11 - Region-based segmentation
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods

IPC Classes  ?

• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/86 - Viral vectors

Abstract

An apparatus (1) for determining an arrhythmia of a living heart (7) comprises a signal evaluation device (3) receiving a signal (6) representing a present electric activity of the heart (7), and determining a frequency spectrum (8, 11-13) of the signal (6). The apparatus (1) further comprises a pulse generator (4) generating a sequence (10) of electric pulses (21) to be applied to the heart (7) at a pulse repetition frequency depending on the frequency spectrum (8, 11-13) and decreasing by at least 20% over the sequence (10).

IPC Classes  ?

• A61N 1/362 - Heart stimulators
• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential

Abstract

The present invention relates to a cell-free enzyme-catalyzed process for producing glycoproteins of general formula (I) from a lipid-linked oligosaccharide and a peptide. Further, said process includes the construction of the lipid-linked oligosaccharide from a mannose trisaccharide containing core structure. Particularly, the lipid-linked oligosaccharide is a high mannose-, complex-, or hybrid-type N-glycan.

IPC Classes  ?

• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The invention relates to a method for vitrifying a biological sample (1). The method includes posi-tioning a sample holder (2) with the biological sample (1) by a transfer device (12) in a starting position (Pi). The sample holder (2) has a base (2a) and a pin (2b) projecting from the base (2a) along a holder axis (A). Further, the biological sample (1) is attached to the pin (2b) distant from the base (2a). The method further comprises adding a liquid to the biological sample (1) in the starting position (Pi) by a liquid dispenser (13). Further, the method comprises moving the sample holder (2) with the biological sample (1) by the transfer device (12) along a predetermined transfer path (T) from the starting position (Pi) to a release position (P2), wherein the biological sample (1) in the release position (P2) is arranged in or adjacent to a liquefied gas (3). It is provided that the transfer path (T) is inclined with respect to the holder axis (A) or runs along a circular arc. Furthermore, the invention relates to a vitrification apparatus (10) which is configured to perform the method.

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation

Abstract

Connectomes of human cortical gray matter require high-contrast homogeneously stained samples sized at least 2-3 mm on a side, and a whole-mouse brain connectome requires samples sized at least 5-10 mm on a side. Here, en-bloc staining and postprocessing protocols are reported, including dehydrating and embedding of neuronal samples, for dense neuronal circuit reconstruction and other applications.

IPC Classes  ?

• G01N 1/30 - StainingImpregnating

Abstract

The present invention relates to the use of the compound of the formula (I) and the composition thereof as control agent for plant diseases caused by fungi, oomycetes and bacteria. Plant pathogens produce self-aggregating proteins, like beta-amyloid proteins, that can be important parts of extracellular structures, for example cell walls, adhesion structures to biological surfaces and other pathogenicity related infection structures. This invention discloses that the compound of the formula (I) interferes with the aggregation of such proteins and thus reduce plant pathogen growth significantly.

IPC Classes  ?

• A01N 43/50 - 1,3-DiazolesHydrogenated 1,3-diazoles
• A01N 43/56 - 1,2-DiazolesHydrogenated 1,2-diazoles
• A01N 43/653 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• A01N 43/76 - 1,3-OxazolesHydrogenated 1,3-oxazoles
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01N 43/82 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with three hetero atoms
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 233/58 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 249/08 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention is concerned with the production of tulipalin A (?-methylene-?- butyrolactone). Provided are methods for production of tulipalin A, recombinant cells or organisms for production of tulipalin A, enzymes needed for the production of tulipalin A, and nucleic acids for expression of those enzymes.

IPC Classes  ?

• C12P 17/04 - Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin

Abstract

It has been surprisingly found that human oocytes lack the important spindle- associated protein KIFC1/HSET. The application describes a method stabilising the human spindle with KIFC1/HSET. Specifically, the method relates to introducing (i) KIFC1/HSET protein or (ii) mRNA encoding KIFC1/HSET into a human oocyte. Furthermore, the application relates to a non-naturally occurring human oocyte, wherein a (i) KIFC1/HSET protein or (ii) KIFC1/HSET mRNA has been introduced into a naturally occurring human oocyte thereby obtaining the non-naturally occurring oocyte. Additionally, the application relates to a (i) KIFC1/HSET protein or (ii) mRNA encoding the KIFC1/HSET for use in a method of lowering the probability of having a disorganized and/or a multipolar spindle during mitosis in a human zygote by introducing the (i) KIFC1/HSET protein or (ii) mRNA encoding the KIFC1/HSET into the human zygote. Moreover, the application discloses a complex comprising (i) a KIFC1/HSET protein and (ii) a human meiotic spindle or a human mitotic spindle, wherein the KIFC1/HSET protein has been introduced into a human oocyte or zygote.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/075 - OocytesOogonia

Abstract

The present invention relates to a method for the diagnosis and/or classification of a disease in a subject based on the genetic and/or epigenetic information of a sample obtained from the subject, the method comprising the steps of: a) providing data from said sample, wherein said data comprises genetic and/or epigenetic information of a random subset of genomic positions; b) assigning said sample to a sample class based on genetic and/or epigenetic information of said random subset of genomic positions by employing a computational model, which discriminates a plurality of sample classes based on genetic and/or epigenetic information of a set of genomic positions comprising said random subset, wherein the computational model has been trained with pre-determined genetic and/or epigenetic information obtained from a plurality of pre-classified samples of known diseases and wherein said computational model processes the genetic and/or epigenetic information of a genomic position of said random subset independently of the genetic and/or epigenetic information of another genomic position of said random subset, wherein said computational model is preferably in the form of a linear classifier with independent feature sampling.

IPC Classes  ?

• G16B 5/20 - Probabilistic models
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 30/10 - Sequence alignmentHomology search
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to a method for transferring a two-spin order of a molecule (e.g. parahydrogen) into a hyperpolarization of at least one heteronucleus, the method comprising the steps of: providing a molecule (e.g. parahydrogen pH2) comprising two protons and at least one heteronucleus (S3, S4), the protons having nuclear spins being coupled to a nuclear spin of the at least one heteronucleus; exposing the protons and the at least one heteronucleus to an e.g. homogeneous magnetic field (B0) in a z-direction, the z-direction forming a right-handed orthogonal coordinate system with an x- and a y-direction; and applying a sequence of radio frequency pulses to the protons and the at least one heteronucleus in order to transfer said two-spin order into the hyperpolarization of the at least one heteronucleus, wherein said sequence of radio frequency pulses comprises a first, a second, and a third group (NA, NB, NC) of 180° radio frequency pulses, wherein the first group (NA) of 180° radio frequency pulses is consecutively applied nA times during a first time interval (?A) and wherein the second group (NB) of 180° radio frequency pulses is consecutively applied nB times during a second time interval (?B) after the last first group, and wherein the third group (NC) of 180° radio frequency pulses is consecutively applied nC times during a third time interval (?C) after the last second group, wherein nA, nB, nC are integer numbers, respectively.

IPC Classes  ?

• G01R 33/46 - NMR spectroscopy
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

The present invention relates to improved methods for obtaining purified contrast agents that are suitable for magnetic resonance imaging. The contrast agents are prepared by a method such dynamic nuclear polarization (DNP), hydrogenative parahydrogen induced polarization (PHIP), or Signal Amplification By Reversible Exchange (SABRE). High degrees of purity are achieved by performing an evaporation step to separate a signal enhanced precursor or the contrast agent from a metal catalyst or a source of radicals.

IPC Classes  ?

• A61K 49/06 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations

Abstract

The present invention relates to a method for attaching a 5'-nicotinamidnucleobasedinucleotide (NND)- capped nucleic acid sequence to a fusion protein or to a complex, comprising (a) contacting (i) a heterologous fusion protein which comprises a poly(peptide) of interest being fused to a tag, or (ii) a complex wherein a protein is under physiological conditions complexed with a tag with the 5'-NAD- capped nucleic acid sequence and an ADP-ribosyltransferase (ART) under conditions wherein the 5'- NND-capped nucleic acid sequence is covalently attached to the tag, wherein the tag comprises a recognition motif of the ART and preferably comprises or consists of (i) SEQ ID NO: 1 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (ii) SEQ ID NO: 2 ora sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (iii) SEQ ID NO: 3 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (iv) SEQ ID NO: 4 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved; (v) SEQ ID NO: 5 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved; or (vi) SEQ ID NO: 6 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved.

IPC Classes  ?

• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
• C07K 19/00 - Hybrid peptides
• C12N 9/10 - Transferases (2.)
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention refers to a process for converting a feed gas stream comprising carbon monoxide and hydrogen as major components (synthesis gas) into higher (C3+) alcohols making use of a catalyst combination of a Fischer-Tropsch catalyst and an olefin hydroformylation catalyst. In a second aspect, the invention relates to a Fischer-Tropsch catalyst suitable to be applied in said process.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• C07C 29/156 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of oxides of carbon exclusively with hydrogen or hydrogen-containing gases characterised by the catalyst used containing iron group metals, platinum group metals, or compounds thereof
• C07C 45/50 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reaction with carbon monoxide by oxo-reactions

Abstract

The present invention is directed to a method for continuous production of cationic lipids. Said cationic lipids are particularly useful in combination with other lipid components for forming lipid nanoparticles with oligonucleotides (e.g. mRNA) to facilitate delivery of therapeutically active nucleic acids.

IPC Classes  ?

• C07C 51/60 - Preparation of carboxylic acid halides by conversion of carboxylic acids or their anhydrides into halides with the same carboxylic acid part
• C07C 55/36 - Acyl halides
• C07C 67/14 - Preparation of carboxylic acid esters from carboxylic acid halides
• C07C 67/313 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
• C07C 69/28 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
• C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton

Abstract

The present invention relates to a vinyl keto ester and intermediates of its synthesis, wherein the vinyl moiety of the vinyl hydroxy ester and of the intermediates is partly or fully deuterated. Furthermore, the present invention relates to two alternative methods of preparing said vinyl keto ester. The first method is a multi-step approach comprising the steps of providing a carboxylic acid that comprises a geminal diol moiety protected by a photolabile protecting group, vinylating said carboxylic acid using vinyl acetate, and cleaving the protecting group by applying UV light. The second method is a one-step approach of reacting a carboxylic acid that comprises an additional carbonyl moiety with acetylene in the presence of a metal catalyst. In both methods, the compounds used may be fully or partly deuterated.

IPC Classes  ?

• C07C 69/738 - Esters of keto-carboxylic acids
• C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings

Abstract

The present invention relates to a method for preparing a compound suitable for signal enhanced magnetic resonance imaging comprising the steps of vinylating a mono-, di- or tricarboxylic acid comprising a moiety -Q-Z with Q being O or N and Z being a protecting group by using vinyl acetate, cleaving Z, and if Z has not already been converted into an alcohol upon cleavage, converting Q into an alcohol either by using nitrite or by converting Q into bromine followed by hydrolysis yielding a vinyl hydroxy ester. The compounds used may be partly or fully deuterated. Furthermore, the present invention relates to a vinyl hydroxy ester as well as an intermediate of its synthesis, wherein the vinyl moiety of the vinyl hydroxy ester and of the intermediate is partly or fully deuterated.

IPC Classes  ?

• C07C 67/307 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogenPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by substitution of halogen atoms by other halogen atoms
• C07C 67/31 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
• C07C 69/68 - Lactic acid esters
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/34 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Abstract

The present invention relates to antisense-oligonucleotides capable of hybridizing with a region of the gene encoding Efnb2, or with a region of the mRNA encoding Efnb2, and salts and optical isomers of said antisense-oligonucleotides for use in prevention of kidney dysfunction promoted by endothelial dysfunction.

IPC Classes  ?

• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Some embodiments relate to a laser oscillator system (10) comprising a resonator cavity (12) for confining an intra-cavity laser beam (13). The laser oscillator system further comprises a Cr-doped II-VI gain medium (14) arranged within the resonator cavity (12), and an imaging unit (18) forming part of the resonator cavity (12). The imaging unit (18) is adapted to decouple a spot size (100) of the intra-cavity laser beam (13) at the gain medium (14) from an intra-cavity length (102) of the resonator cavity (12). Moreover, the resonator cavity (12) and the imaging unit (18) are adapted such that the laser oscillator system (10) emits laser pulses at a repetition rate of 50 MHz or less. Further embodiments relate to a laser system (30) and to methods for generating light pulses having spectral components at a wavelength of at least 2 µm.

IPC Classes  ?

• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 3/08 - Construction or shape of optical resonators or components thereof
• H01S 3/0941 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light of a semiconductor laser, e.g. of a laser diode
• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• H01S 3/105 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling the mutual position or the reflecting properties of the reflectors of the cavity
• H01S 3/11 - Mode lockingQ-switchingOther giant-pulse techniques, e.g. cavity dumping
• H01S 3/16 - Solid materials

Abstract

An embodiment relates to a laser system (20) for generating laser pulses having a determined carrier-envelope-offset, CEO. The laser system (20) comprises a Cr- doped ll-VI based laser oscillator system (22) having a resonator cavity (112), wherein the laser oscillator system (22) is adapted to emit laser pulses (10) from the resonator cavity (112) having a peak power of at least 0,75 MW. The laser system further comprises a nonlinear optical element (26) for spectrally broadening at least a part of the emitted laser pulses (10) irradiated onto the nonlinear optical element to provide the laser pulses (10) with octave-spanning spectral components, and a frequency-doubling element (34) for generating second harmonic spectral components of at least a part of the octave-spanning spectral components of the spectrally broadened laser pulses (10) when irradiating the spectrally broadened laser pulses (10) onto the frequency-doubling element (34), such that a part of the second harmonic spectral components spectrally overlap with a part of the remaining octave-spanning spectral components of the laser pulses (10). In addition, the laser system comprises a f-2f-interferometry device (40) for generating a beating signal of at least a part of the overlapping spectral components exiting the frequency-doubling element (34) and interfering with each other at the f-2f-interferomtry device and for determining and/or controlling the CEO of the emitted laser pulses (10) based on the beating signal. Another embodiment relates to a method for generating laser pulses (10) having a determ ined carrier-envelope-offset.

IPC Classes  ?

• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 3/08 - Construction or shape of optical resonators or components thereof
• H01S 3/0941 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light of a semiconductor laser, e.g. of a laser diode
• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• H01S 3/105 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling the mutual position or the reflecting properties of the reflectors of the cavity
• H01S 3/11 - Mode lockingQ-switchingOther giant-pulse techniques, e.g. cavity dumping
• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• H01S 3/131 - Stabilisation of laser output parameters, e.g. frequency or amplitude by controlling the active medium, e.g. by controlling the processes or apparatus for excitation
• H01S 3/136 - Stabilisation of laser output parameters, e.g. frequency or amplitude by controlling devices placed within the cavity
• H01S 3/16 - Solid materials

Abstract

The present invention relates to a guide RNA (gRNA) suitable for CRISPR-mediated oligonucleotide binding and/or editing comprising at least one hairpin that does not interact with a Cas enzyme wherein said hairpin forms a locked secondary structure.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a composition comprising at least one inhibitor of mitochondrial transcription (IMT) and at least one anti-cancer drug. Furthermore, the present invention is directed to compositions for use as a medicament and to compositions for use in the treatment and/or prevention of cancer.

IPC Classes  ?

• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a monoclonal antibody 3D9 specifically binding a C-terminal fragment of cleaved histone H3 in NETs that can be used to specifically detect NETs distinguishing them from chromatin of different origin. The invention also provides a method for in vitro detection of neutrophil extracellular traps in isolated biological samples as well as a method for assessing a disease condition associated with NET formation. The present invention also relates to an isolated fragment of human histone H3 cleaved at site L48R49, and to the use of cleavage site L48R49 for specific detection of human neutrophil extracellular traps. The present invention also relates to recombinant nucleic acid sequences encoding said polypeptides, and host cells comprising the same.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates in a first main aspect to self-supporting mistletoe viscin films comprising a 2-dimensional multi-axial oriented array of viscin cellulose filaments within a humidity-responsive matrix and methods for preparing the same. A further aspect relates to 2D and 3D mistletoe viscin scaffolds and methods for preparing the same. Another main aspect of the invention relates to the use of mechanically isolated mistletoe viscin or of said self-supporting mistletoe viscin films for joining or binding together a plurality of materials with diverse surface characteristics and to an adhesive comprising such viscin films and/or 2D or 3D viscin scaffolds. In more specific embodiments, the invention relates to a wound sealant and coating composition or to a medical kit comprising mechanically isolated mistletoe viscin in the hydrated/wet state and a plant oil, or a dried viscin film for use, after rehydration under humid conditions, as a wound sealant.

IPC Classes  ?

• A61L 24/08 - Polysaccharides

Abstract

The present invention relates to an efficient process for the preparation of nanocelluloses using mixtures of ammonium formate and at least one acid as reactant and solvent as well as to novel modified nanocelluloses and their applications.

IPC Classes  ?

• C08B 15/06 - Derivatives containing elements other than carbon, hydrogen, oxygen, halogen, or sulfur containing nitrogen
• C08B 15/08 - Fractionation of cellulose, e.g. separation of cellulose crystallites
• C08L 1/04 - OxycelluloseHydrocellulose
• D21C 9/00 - After-treatment of cellulose pulp, e.g. of wood pulp, or cotton linters
• D21H 11/18 - Highly hydrated, swollen or fibrillatable fibres
• D21H 11/22 - Chemically or biochemically modified fibres cationised

Abstract

The invention relates to a delivery device formed by an aggregation of a plurality of individual particles in a host fluid, wherein one or more individual particles of the plurality of individual particles has a density of less than the host fluid, preferably less than water, and a bonding property which permits the initially separate individual particles to aggregate in said host fluid, i.e. to be connected one to another in said host fluid, to form the aggregation. The invention further relates to a method for producing a plurality of individual particles and to a method of forming a delivery device from a plurality of particles in a host fluid at an aggregation site.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 49/04 - X-ray contrast preparations
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 49/22 - Echographic preparationsUltrasound imaging preparations
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• B32B 15/02 - Layered products essentially comprising metal in a form other than a sheet, e.g. wire, particles
• C09B 67/02 - Dyestuff preparations characterised by special physical forms, e.g. tablets, films

Abstract

A method (1) for preparing a laser marking system (100) to create a colored laser mark on a specimen comprising the following steps: a) Providing a laser marking system (100) and a specimen (105) comprising a surface layer (105a), wherein the laser marking system comprises a preset number of laser parameters (12); b) Performing an exploration of a first gamut (2) specified by the laser marking system (100) and the specimen (105) comprising a surface layer (105a) including the following steps: aa) Creating (3) a design space (10) with a preset number of design points (11), wherein each design point (11) represents a combination of the preset number of laser parameters (12); bb) Performing (4) a marking of a sample on the specimen (105) for each design point (11); cc) Measuring (5) the sample using at least one detection device (106) and deter- mine for each design point a performance point (14), wherein the measured performance points (14) define a performance space (13); dd) Evaluating (6) the performance space (13) with regard to preset performance criteria using an evaluation device (107), wherein a Pareto front is determined comprising a subset of performance points; ee) Generating (7) an offspring design space (10a) with offspring design points (11a); ff) Creating (8) a first gamut (2) using the subset of performance points forming the Pareto front; wherein the steps bb) to dd) are iterated (9) for a preset iteration number, wherein in each iteration (9) the offspring design space (10a) of the previous iteration is used in step bb), wherein in each iteration the measured performance space is combined (15) with the performance space of the previous iteration (9) such that in step dd) the combined performance space (13a) is used.

IPC Classes  ?

• B41M 5/26 - Thermography
• B41M 5/34 - Multicolour thermography
• G11B 7/00 - Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation, reproducing using an optical beam at lower powerRecord carriers therefor
• G11B 7/005 - Reproducing

Abstract

The present disclosure provides a conjugate comprising an affinity agent, a branched linker, and two or more photoisomerizable regulators. The present disclosure provides compositions comprising the conjugate, as well as devices comprising the compositions. The present disclosure provides methods for enhancing visual function, the methods comprising administering the conjugate to an individual in need thereof.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 5/079 - Neural cells

Abstract

The present invention relates to a method for producing cytidine 5'-monophospho-N-acetyl-neuraminic acid (CMP-Neu5Ac, 1) from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, cytidine and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3). Further, said process may be adapted to produce Neu5Acylated i.e. sialylated biomolecules and biomolecules including a saccharide, a peptide, a protein, a glycopeptide, a glycoprotein, a glycolipid, a glycan, an antibody, and a glycoconjugate, in particular, an antibody drug conjugate, and a carbohydrate conjugate vaccine, or a flavonoid.

IPC Classes  ?

• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• C12P 19/26 - Preparation of nitrogen-containing carbohydrates
• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides

Abstract

Described is a method for the incorporation of formaldehyde into biomass comprising the following enzymatically catalyzed steps (1) condensation of pyruvate with formaldehyde into 4-hydroxy-2-oxobutanoic acid (HOB); (2) amination of the thus produced 4-hydroxy-2-oxobutanoic acid (HOB) to produce homoserine; (3) conversion of thus produced homoserine to threonine; (4) conversion of the thus produced threonine into glycine and acetaldehyde or acetyl-CoA; (5) condensation of the thus produced glycine with formaldehyde to produce serine; and (6) conversion of the thus produced serine to produce pyruvate, wherein said pyruvate can then be used as a substrate in step (1).

IPC Classes  ?

• C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide

Abstract

The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four a-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming a-helices that are located on the same polypeptide chain, wherein each amino acid linker has a length between 2 and 20 amino acids. The invention also provides for a polynucleotide and a vector encoding the protein of the invention, host cells comprising said polynucleotide, a method for producing the protein of the invention and a pharmaceutical composition comprising the protein of the invention. The invention further relates to uses of the proteins of the invention as a research reagent and the use of the protein and/or pharmaceutical composition comprising the same as a medicament, e.g., for use in increasing stem cell production, for use in inducing hematopoesis and/or for use in mobilizing hematopoietic stem cells.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/535 - Granulocyte CSFGranulocyte-macrophage CSF
• C07K 19/00 - Hybrid peptides
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 15/27 - Colony stimulating factors
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention relates to a genetically engineered microorganism expressing (i) formate tetrahydrofolate (THF) ligase, methenyl-THF cyclohydrolase and methylene-THF dehydrogenase, (ii) the enzymes of the glycine cleavage system (GCS), (iii) serine deaminase and serine hydroxymethyltransferase (SHMT), (iv) an enzyme increasing the availability of NADPH, and (v) optionally formate dehydrogenase (FDH), and wherein the genetically engineered microorganism has been genetically engineered to express at least one of the enzymes of (i) to (v), wheren said enzyme is not expressed by the corresponding microorganism that has been used to prepare the genetically engineered microorganism, and wherein the enzymes of (i) to (v) are genomically expressed.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• C12N 9/10 - Transferases (2.)
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 9/88 - Lyases (4.)
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group

Abstract

The present invention relates to compounds represented by general formula (la), (lb), (lla) or(llb). These compounds are suitable for imaging alpha-synuclein and for diagnosing diseases which are associated with the aggregation of alpha-synuclein. The compounds are also useful for treating and preventing diseases which are associated with the aggregation of alpha-synuclein.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 49/00 - Preparations for testing in vivo
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention relates to the provision of new means and methods for enzymatic peptide-peptide ligation. In particular, the present invention provides a novel family of transpeptidase enzymes, herein subsequently also referred to as Adriase (Archaeal Peptide Recombinase), transpeptidase or polypeptide recombinase. The members of the Adriase family, which are characterized by an N-terminal DUF2121 domain with an N-terminal serine or threonine residue were surprisingly found to recombine and ligate substrate peptides in a sequence specific manner via a short DUF2121 recognition motif. This way, compounds like proteins, synthetic compounds and/or whole cells may be linked specifically as long as they contain the motif or the parts thereof recognized by an Adriase enzyme. The ligation reaction described herein can be used to engineer novel molecules in a modular way, with broad applications in both research and pharmacology.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 19/00 - Hybrid peptides
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 9/10 - Transferases (2.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention relates to an enzyme-catalyzed process for producing UDP-galactose from low-cost substrates uridine monophosphate and D-galactose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Said process can be extended to uridine as starting material instead of uridine monophosphate. Further, said process can be adapted to produce galactosylated molecules and biomolecules including saccharides, proteins, peptides, glycoproteins or glycopeptides, particularly human milk oligosaccharides (HMO) and (monoclonal) antibodies.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/14 - Hydrolases (3.)
• C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/30 - Nucleotides
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention relates to an enzyme-catalyzed process for producing UDP-N-acetyl-a-D-glucosamine (UDP-GlcNAc) from low-cost substrates uridine monophosphate and N-acetyl-D glucosamine in a single reaction mixture with immobilized or preferably co-immobilized enzymes. Uridine may be used as starting material instead of uridine monophosphate as well. Further, said process may be adapted to produce GlcNAcylated molecules and biomolecules including saccharides, particularly human milk oligosaccharides (HMO), proteins, peptides, glycoproteins, particularly antibodies, or glycopeptides, and bioconjugates, particularly carbohydrate conjugate vaccines and antibody-drug conjugates.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/14 - Hydrolases (3.)
• C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/30 - Nucleotides
• C12P 21/00 - Preparation of peptides or proteins

Abstract

Molecular determinants of cancer response to immunotherapy are described.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to the field of single-domain antibodies (sdAb) directed towards the glycans of the globo series, and in particular Globo H. More in detail, the present invention relates to sdAbs specifically binding one or more glycans selected from Globo H, Gb3, Gb4, and Gb5. The invention also provides polypeptides comprising multimeric single domain antibodies, as well as T cell chimeric antigen receptors comprising said anti-glycan sdAbs. Thus, the present invention provides polypeptides that can be used for targeting and/or treating several types of cancers associated with cells over-expressing said Globo H and /or Gb3, Gb4, Gb5. The present invention also relates to recombinant nucleic acid sequences encoding said polypeptides, and expression vectors and host cells comprising the same.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 15/13 - Immunoglobulins
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to a system for displaying information, comprising: an emission device arranged to emit light so as to display information to a user, the emission device being adapted to emit the light in a pulsed manner so that the intensity of the light varies between a high value and a low value, a selective viewing device comprising a panel, the panel being adapted so that the user can view the light which is emitted by the emission device through that panel so as to visually perceive the information being displayed, the panel having a variable transparency which can be varied between a state of high transparency and a state of low transparency, the system being adapted to synchronize the emission device and the selective viewing device so that the states of the emission device emitting light at a high-intensity value and the states of the panel of the selective viewing device of high transparency overlap in time, the system further comprising a photoelectric conversion means arranged to convert ambient light into electric energy so as to feed the electric energy into the system.

IPC Classes  ?

• G09G 3/34 - Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix by control of light from an independent source

Abstract

The present invention relates to transgenic plants with altered photorespiration and improved CO2 fixation as well as a method of producing said transgenic plants. Particularly, the transgenic plants show an improved growth rate, productivity and energy conversion efficiency. This method can be successfully applied to many agricultural croop plants with nutritional and medicinal uses.

IPC Classes  ?

• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• C12N 9/10 - Transferases (2.)
• C12N 9/88 - Lyases (4.)
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/54 - Transferases (2)
• C12N 15/60 - Lyases (4)
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

An optical resonator device (100) with crossed cavities, in particular being configured for optically trapping atoms, comprises a first linear optical resonator (10) extending between first resonator mirrors (11A, 11B) along a first resonator light path (12) and supporting a first resonator mode, a second linear optical resonator (20) extending between second resonator mirrors (21A, 21B) along a second resonator light path (22) and supporting a second resonator mode, wherein the first and second resonator light paths (12, 22) span a main resonator plane, and a carrier device carrying the first and second resonator mirrors (11A, 11B, 21A, 21B), wherein the first and second resonator mirrors (11, 21) are arranged such that the first and second resonator modes cross each other for providing an optical lattice trap (1) in the main resonator plane. The carrier device comprises a monolithic spacer body (30) being made of an ultra-low-expansion material and comprising first carrier surfaces (31) accommodating the first resonator mirrors (11A, 11B) and second carrier surfaces (32) accommodating the second resonator mirrors (21A, 21B), wherein the first resonator light path (12) extends through a first spacer body bore (33) in the spacer body (30) between the first carrier surfaces (31), and the second resonator light path (22) extends through a second spacer body bore (34) in the spacer body (30) between the second carrier surfaces (32). Furthermore, an atom trapping method for creating a two-dimensional arrangement of atoms and an atom trap apparatus, like an optical atomic clock, a quantum simulation and/or a quantum computing device are described.

IPC Classes  ?

• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks

Abstract

The present invention relates to an enzyme-catalyzed process for producing GDP-fucose from low-cost substrates guanosine and L-fucose or guanosine and D-Mannose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Further, said process can be adapted to produce fucosylated molecules and biomolecules including glycans, such as human milk oligosaccharides, proteins, peptides, glycoproteins or glycopeptides.

IPC Classes  ?

• C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide

Abstract

In a first aspect, the present invention relates to new recombinant polypeptides derived from the newly identified gamma subunit of the fatty acid synthase protein complex. In addition, a fatty acid synthase protein complex comprising these new recombinant polypeptides are disclosed as well as nucleic acid molecules encoding these polypeptides. Further, a host cells containing the nucleic acid molecule encoding the polypeptides according to the present invention or expressing the polypeptide according to the present invention are described. In addition, an isolated fatty acid synthase protein complex is disclosed containing the newly identified gamma subunit thereof. Moreover, methods for determining the suitability of candidate compounds capable of inhibiting either the ketoreductase, enoylreductase or malonyl/palmitoyl transferase present in the FAS protein complex and methods for designing inhibitors of said enzymes are disclosed. Finally, the present invention relates to the inhibitors and their use in medicinal applications.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to methods for producing solid supports. The present invention further provides a mixture of said solid supports for tagmentation of target DNA for DNA sequencing approaches, a corresponding kit comprising the same and methods employing said mixture of solid supports and/or kit. Specifically, methods for producing sequencing libraries and corresponding DNA sequencing methods for analyzing the generated sequencing libraries and tools used therein are provided. In particular, DNA sequencing approaches allowing preservation of contiguity information of long DN A fragments even when using short read sequencing approaches are disclosed. A key concept of the present invention is to employ segmented barcodes, with every barcode segmented allowing for barcode error detection and correction on a segment level. Preferred barcode sequences employed are characterized in that they comprise no linker sequences or only linker sequences of one or two nucleotides in length between the barcode segments.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to improved (simplified/easier, more robust and more reproducible) methods for identification of carbohydrates compositions, e.g. out of complex carbohydrate mixtures, as well as the determination of carbohydrate mixture composition patterns (e.g.: of glycosylation patterns) based on advanced internal standards to determine precise and highly reproducible migration and retention time indices using novel fluorescent dyes in combination with high performance separation technologies, like capillary (gel) electrophoresis (C(G)E) or (ultra)high performance liquid chromatography (U)HPLC with a highly sensitive detection like (laser induced) fluorescence detection. In a first aspect, the present invention relates to methods for an automated determination and/or identification of carbohydrates and/ or carbohydrate mixture composition pattern profiling as well as a method for an automated carbohydrate mixture composition pattern profiling based on the use of at least a first and second fluorescent label for labelling the migration/retention time alignment standard and sample or different samples, respectively, whereby the at least one of that fluorescent dye is a compound as defined herein. Moreover, the present invention relates to a method for calibration of multi wavelength fluorescence detection systems as well as calibration systems or calibration standards and new compounds suitable for calibration are described. The present invention relates further to a kit or system for determining or identifying carbohydrate mixture composition patterns as well as a kit or system for determining and/or identifying carbohydrate mixture composition pattern. Further, a carbohydrate dye conjugate comprising the dye as defined herein for use in a method according to the present invention is provided. The dyes employed for forming the carbohydrate dye conjugate have formula A or B below:

IPC Classes  ?

• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07H 15/24 - Condensed ring systems having three or more rings
• C09K 11/07 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials having chemically-interreactive components, e.g. reactive chemiluminescent compositions
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 21/64 - FluorescencePhosphorescence
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor

Abstract

Sulfonated 2(7)-aminoacridone and 1-aminopyrene dyes and their use as fluorescent tags, in particular for carbohydrate analysis The invention relates to fluorescent dyes with multiple negatively charged groups in their ionized form which are aminoacridone sulfonamides or 1-aminopyrenes having of one of the following general formulae A-D: Formula (A), Formula (B), Formula (C), Formula (D), wherein the ionizable groups X are typically selected from the following: SH, COOH, SO3H, OSO3H, OP(O)(OH)2, OP(O)(OH)Ra, P(O)(OH)2, P(O)(OH)Ra, where Ra= C1-C4alkyl or substituted C1-C4alkyl. The invention further relates to the use of these dyes as fluorescent tags, in particular for reducing sugars and glycans.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07C 311/16 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
• C07D 219/08 - Nitrogen atoms
• C09B 57/00 - Other synthetic dyes of known constitution
• G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to compounds suitable to increase precise genome editing efficiency in a eukaryotic target cell or target organism. Thus, the present invention can be applied in gene therapy.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to a method of producing organoids, said method comprising or consisting of: (a) seeding a plurality of tissue-specific precursor cells into a container; (b) allowing to occur (i) aggregation of said cells; and (ii) maturation of the aggregate formed in (i) into a single organoid; wherein said method does not comprise embedding of said cells or said aggregates into a gel.

IPC Classes  ?

• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

The present invention relates to 2,6-methanobenzo[g][1]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds.

IPC Classes  ?

• A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 491/08 - Bridged systems

Abstract

An interferometer apparatus for an achromatic interferometric superposition of electromagnetic fields, with a dual beam path interferometer, comprises a beam splitter being arranged for splitting an input beam into a first beam propagating along a first interferometer arm (A1) including at least one deflection mirror and a second beam propagating along a second interferometer arm (A2) including at least one deflection mirror, wherein the first and second interferometer arms have an identical optical path length, and a beam combiner being arranged for recombining the first and second beams into a constructive output and a destructive output, wherein reflective surfaces of the beam splitter and the beam combiner are arranged such that, in the first interferometer arm compared with the second interferometer arm, one additional Fresnel reflection at an optically dense medium is provided and a propagation of the electromagnetic fields of the first and second beams, when recombined by the beam combiner, results in a wavelength-independent phase difference of p between the contributions of the two interferometer arms to the destructive output, and the first interferometer arm includes a balancing transmission element being arranged for balancing a chromatic dispersion and Fresnel losses in the first and second interferometer arms. Furthermore, an interferometric measurement apparatus and an interferometric measurement method are described.

IPC Classes  ?

• G01B 9/02015 - Interferometers characterised by the beam path configuration
• G01B 9/02055 - Reduction or prevention of errorsTestingCalibration
• G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry

Abstract

The present invention relates to a fusion protein, comprising the structure N- PCSY - degSigN - M - PCSX - degSigC -C; wherein N represents the N-terminus; PCSY and PCSX each represent a protease cleavage site (PCS), which differ from each other in at least one amino acid residue; degSigN represents a degradation signal which promotes degradation of the fusion protein in a host cell if PCSY is cleaved by a protease such that the first amino acid of degSigN becomes the new N-terminus of the remaining fusion; M represents a cytoplasmic selection marker; and degSigC represents a second degradation signal which promotes degradation of the fusion protein in a host cell if PCSX is not cleaved by a protease; and C represents the C-terminus. Further provided is a nucleic acid construct, comprising a nucleic acid sequence coding for said fusion protein, a nucleic acid expression construct library, comprising a plurality of such nucleic acid expression constructs in diversified form, and methods using the fusion protein and nucleic acid constructs coding therefor. Finally, the present invention provides variants of bdSUMO and bdSENP1 which have been identified by the methods of the present disclosure, and which exhibit improved properties over existing orthogonal protease/protease cleavage site-pairs which are currently used with wild-type bdSUMO and wildtype bdSENP1.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/60 - Proteinases derived from fungi from yeast
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The invention relates to a system for displaying information to a user, comprising: an emission device (12, 13) arranged to emit light so as to display information to a user (18), the emission device (12, 13) being adapted to emit the light in a pulsed manner so that the intensity of the light varies between a high value and a low value, a selective viewing device (16) comprising a panel, the panel being adapted so that the user can view the light (11') which is emitted by the emission device through that panel so as to visually perceive the information being displayed, the panel having a variable transparency which can be varied between a state of high transparency and a state of low transparency, the system being adapted to synchronize the emission device (12, 13) and the selective viewing device (16) so that the states of the emission device emitting light at a high-intensity value and the states of the panel of the selective viewing device of high transparency overlap in time, the emission device being adapted so that the light is emitted in a pulsed manner with a duty cycle of less than or equal to 1/10, wherein the panel of the selective viewing device is adapted to operate at essentially the same duty cycle.

IPC Classes  ?

• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
• G09G 3/00 - Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
• H04N 13/00 - Stereoscopic video systemsMulti-view video systemsDetails thereof

Abstract

Disclosed are a device, system and method for animal tracking. The tracking device comprises a tracker processing component, an energy component, a transmitting component, and a securing component. The system comprises the tracking device, a receiving device and a server. The method comprising securing the tracking device to an animal, transmitting an identification of the animal, receiving the transmission via the receiving device, modifying it and forwarding it to the server, where the modified transmission is logged and analyzed to determine animal positions.

IPC Classes  ?

• A01K 11/00 - Marking of animals
• A01K 29/00 - Other apparatus for animal husbandry
• G01S 5/00 - Position-fixing by co-ordinating two or more direction or position-line determinationsPosition-fixing by co-ordinating two or more distance determinations
• H04W 84/10 - Small scale networksFlat hierarchical networks

Abstract

The invention relates to a method of determining an association of a first plant with an arbuscular mycorrhizal fungus (AMF), said method comprising comparing the amount of a blumenol in an aerial part of said first plant to the amount of said blumenol in an aerial part of a second plant, wherein said second plant belongs to the same species as said first plant, and wherein an increased amount is indicative of increased association in said first plant as compared to said second plant, and a decreased amount is indicative of decreased association.

IPC Classes  ?

• A01H 1/04 - Processes of selection
• A01H 3/00 - Processes for modifying phenotypes
• A01H 17/00 - Symbiotic or parasitic combinations including one or more new plants, e.g. mycorrhiza
• C12N 1/14 - Fungi Culture media therefor
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a computer-implemented method of calculating the ranges of concentrations, of fluxes, or of reaction rate constants in a network of chemical reactions.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Abstract

The present invention relates to the use of a vehicle for specific molecular targeting of Langerin+ cells, wherein the vehicle is capable of specifically binding to a Langerin+ cell, said vehicle comprising (a) at least one carrier and (b) at least one saccharide moiety-based conjugate for a targeted cargo delivery into a Langerin+ cell, as well as pharmaceutical compositions and uses comprising the inventive vehicle.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to novel anti-IgG nanobodies, particularly nanobodies directed against rabbit or mouse IgG. Further, the invention relates to the use of said nanobodies and methods for producing them.

IPC Classes  ?

• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Abstract

The invention relates to a device for frictionless and lubricant-free movement in vacuum, wherein the device comprises a positionally fixed rail and a rail that can be moved relative thereto by means of magnetic force. The invention further relates to a vacuum chamber, for example for a coating installation comprising a device according to the invention.

IPC Classes  ?

• F16C 29/04 - Ball or roller bearings
• F16C 32/04 - Bearings not otherwise provided for using magnetic or electric supporting means

Abstract

Intravitreal delivery of the therapeutic and imaging nanoparticles promised considerable potential applications in the field of the ocular medicine, while the slow and random passive diffusion of the particles in vitreous are prompting novel strategies for rapid delivery to target site in the back of the eye. Here, we report the first microparticles that actively propel through the vitreous humour and reach the retina in porcine eyes. The slippery micro helical propellers are constructed by the combination of glancing angle deposition technique and the fusion of the slippery liquid layer. The magnetically propulsion in the vitreous humour relies on the matched size of the propeller to the collagen network of the vitreous, and the anti-adhesion coating of the collagen fibre bundles. The clinical optical coherence tomography observed the displacement of the slippery micropropellers through the vitreous to the macular area on the retina. The slippery micropropellers realized the controllable massive movements to the retina in 30 mins, while exerting the travelling distance of above one centimetre. Therefore, the injection of the slippery micropropellers, the magnetically-powered controllable propulsion in the vitreous, and the optical coherence tomography imaging technique, constitute an intact method for rapid targeted ocular delivery, providing a promising approach towards ophthalmologic applications.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 49/00 - Preparations for testing in vivo
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to newly characterized light-inducible inward proton pumps and their use in medicine, their utility as optogenetic tools, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61N 5/06 - Radiation therapy using light
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 1/16 - YeastsCulture media therefor

Abstract

A method to set a propeller into locomotion relative to a medium at least partially surrounding the propeller comprises using an actuator to induce a rotation of the propeller relative to the medium and about a rotational axis of the propeller. The propeller converts rotational movement of the propeller into locomotion of the propeller relative to the medium. An aspect ratio of at least one cross section of the propeller perpendicular to the rotational axis is 3 or more. On the at least one cross section a rotational centre is inside of the propeller.

IPC Classes  ?

• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery

Abstract

The present invention relates to compounds, compositions and kits suitable to precise genome editing efficiency in a eukaryotic target cell or target organism.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A method of measuring a polarization response of a sample including generating a sequence of excitation waves, irradiating the sample with excitation waves, so that a sequence of sample waves is generated each including a superposition of a sample main pulse and a sample global molecular fingerprint (GMF) wave, irradiating a reference sample with the excitation waves, so that a sequence of reference waves is generated each including a superposition of a reference main pulse and a reference GMF wave, optically separating a difference of the sample waves and reference waves from GMF wave contributions which are common to both of the sample waves and reference waves in space and/or time, and detecting the difference of the sample waves and the reference waves and determining a temporal amplitude of differential molecular fingerprint waves each comprising the difference of the sample and reference GMF waves.

IPC Classes  ?

• G01N 21/3586 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation by Terahertz time domain spectroscopy [THz-TDS]
• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G01N 21/65 - Raman scattering

Abstract

An apparatus (1 ) for terminating or unpinning rotating electric activity (2) in a cardiac tissue (3), the apparatus (1 ) comprises an electric state sensor sensing at least one electric parameter of the cardiac tissue; an electric state analyzer (9) connected to the electric state sensor (8) and analyzing the at least one electric parameter for rotating electric activity (2) in the cardiac tissue (3); a pulse generator (19) connected to the electric state analyzer (9) and generating electric pulses in response to rotating electric activity (2) in the cardiac tissue (3); and a pulse applicator (20) connected to the pulse generator (19) and applying the electric pulses as electric field pulses extending across the cardiac tissue (3). The electric pulses include a rotating electric activity termination or unpinning pulse (28) and a plurality of rotating electric activity synchronization pulses (27) preceding the rotating electric activity termination or unpinning pulse (28). The rotating electric activity synchronization pulses (27) are arranged at first intervals (Tsync), and the rotating electric activity termination or unpinning pulse (28) is arranged at a second interval (At) in a range from 0.7 to 1.2 times one of the first intervals (Tsync) after the last one of the plurality of rotating electric activity synchronization pulses (27). At least one of a first maximum electric field strength (FSsync) as caused by each of the rotating electric activity synchronization pulses (27) and a first electric pulse energy (PEsync) delivered to the cardiac tissue (3) by each of the rotating electric activity synchronization pulses (27) is not more than 82 % of a second maximum electric field strength (FStou) as caused by the rotating electric activity termination or unpinning pulse (28) or not more than 67 % of a second electric pulse energy (PEtou) delivered to the cardiac tissue (3) by the rotating electric activity termination or unpinning pulse (28), respectively.

IPC Classes  ?

• A61N 1/362 - Heart stimulators
• A61N 1/39 - Heart defibrillators

Abstract

The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid- modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

A measurement device comprises neuronal, in particular retinal, tissue grown from stem cells, the neuronal tissue having a three-dimensional shape neuronal cells that change an electric potential in cells of the neuronal tissue in response to influences that act on the neuronal cells, and a read-out device that is configured to measure neuronal responses of the neuronal tissue via changes in the electric potential generated by the neuronal cells.

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61L 27/38 - Animal cells
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/079 - Neural cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 3/00 - Condition-responsive control processes

Abstract

A method and apparatus is provided for implementing a parametric down-conversion (PDC)-based calibration comprising calibrating a measuring instrument; disposing a pinhole at a position of a light-emitting sample for which the measuring instrument needs to be calibrated; irradiating a nonlinear crystal with a light source; setting the nonlinear crystal by ensuring a phase-matching wavelength of the nonlinear crystal is set at one boundary of a desired bandwidth; acquiring one or more PDC spectrums by the measuring instrument; obtaining peak values and their corresponding wavelengths from each acquired spectrum; and obtaining a response function based on the peak values and corresponding wavelengths.

IPC Classes  ?

• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/28 - Investigating the spectrum

Abstract

The present invention provides a stable synthetic saccharide of Hib polyribosylribitol- phosphate (PRP) derivative and conjugate thereof. Said saccharide, said conjugate and pharmaceutical compositions thereof are hydrolysis-resistant, long-term stable and useful for the prevention and/or treatment of diseases associated with Haemophilus influenzae, and more specifically of diseases associated with Haemophilus influenzae type b, preferably diseases selected from meningitis, pneumonia, and epiglotitis.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a compound of formula (I), wherein X is C=0, C=S or B-OH; Y is an electrophile and Z is a leaving group, or Y--Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery; or (b) a group binding between subunits ß1 and ß2 of a proteasome; R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.

IPC Classes  ?

• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided. Said method is particularly useful in personalized medicine identifying suitable inhibitors of the 20S proteasome in individuals for treating, ameliorating or preventing a cancer, an autoimmune disease, a muscular dystrophy, emphysema or cachexia accompanying cancer or AIDS.

IPC Classes  ?

• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/32 - ExtractionSeparationPurification by precipitation as complexes
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types

Abstract

This invention relates to a method of determining ligands of macromolecules, said method comprising or consisting of (a) subjecting a sample comprising (i) complexes formed by said macromolecules and said ligands and (ii) unbound ligands to a method which separates said complexes from said unbound ligands; (b) releasing ligands from complexes obtained in step (a); and (c) subjecting the released ligands obtained in step (b) to a chemical analysis method, thereby determining said ligands of said macromolecules.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

An apparatus for applying at least one electric pulse to a living myocardial tissue comprises an input receiving an electric signal representing a present electric activity of the myocardial tissue; a signal processor (11) processing the electric signal to determine a measure of the present complexity of the electric signal in the state space and to output a control signal (13) when the complexity measure is lower than a predetermined complexity threshold value; a pulse generator configured to generate the at least one electric pulse in response to the control signal; and an output configured to output the at least one electric pulse to the myocardial tissue.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/362 - Heart stimulators
• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential

Abstract

The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with Helicobacter pylori, in particular H. pylori infection and gastroduodenal disorders caused by H. pylori. The present invention further relates to methods of detecting H. pylori infection in a subject.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens

Abstract

The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD).(see formula Ia) (see formula Ib)The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain, 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07F 9/11 - Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl

Abstract

An apparatus for producing elongate fibers of metal, metallic glasses or inorganic material comprises a rotatable wheel having a planar external circumferential surface, which is flat in a direction parallel to the axis of rotation of the wheel, at least one nozzle having a nozzle opening for directing a molten metal onto the circumferential surface and a collection means for collecting solidified fibers of metal formed on the circumferential surface from the molten metal and separated from the circumferential surface by centrifugal force generated by rotation of the wheel. The nozzle has a rectangular cross-section having a width of the nozzle opening in the circumferential direction of rotation of the wheel and a length transverse to the circumferential surface of the wheel which is greater than the width. An apparatus is provided for controlling a gas pressure applied to the liquid metal which moves the liquid metal through the nozzle opening and delivers it to the circumferential surface of the rotatable wheel. A method of producing elongate fibers is also claimed.

IPC Classes  ?

• B22D 11/00 - Continuous casting of metals, i.e. casting in indefinite lengths
• B22D 11/112 - Treating the molten metal by accelerated cooling

Abstract

The present invention relates to a method for determining in an expedient manner and with minimal sample consumption the structure of an unknown carbohydrate by using ion mobility-mass spectrometry (IM-MS) in negative ionization mode and fragmentation and a database containing structures of carbohydrates and/or of the fragments of the negative ions of carbohydrates, andfor each of the structures of the target carbohydrates the collision cross section value and the mass-to-charge ratio value of the negative ion thereof, and for each of the structures of the fragments of the negative ions of the target carbohydrates the collision cross section value and the mass-to-charge ratio value of the fragment of the negative ion of the target carbohydrate.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides an improved hollow-core fibre of non-bandgap type including extended wavelength range of single-mode transmission, increased loss of higher order modes (HOM) and the fundamental, and increased ratio in loss between the highest-index core HOM and the LP01 mode. A hollow-core anti-resonant-reflecting fibre (HC-AF) includes a hollow-core region, an inner cladding region, and an outer cladding region. The hollow-core region axially extends along the HC-AF. The inner cladding region includes a plurality of anti-resonant elements (AREs) and surrounds the hollow-core region. The outer cladding region surrounds the inner cladding region. The hollow-core region and the plurality of AREs are configured to provide phase matching of higher order hollow-core modes and ARE modes in a broadband wavelength range.

IPC Classes  ?

• G02B 6/02 - Optical fibres with cladding

Abstract

The present invention relates to a use of a tertiary amine as buffer in sample preparation, preferably for mass spectrometry and/or UV/vis spectroscopy, wherein the sample comprises proteins, polypeptides and/or peptides, and said sample preparation comprises: (a) protein, polypeptide and peptide denaturation; and (b) chemical isotope labelling and/or chemical cross-linking, wherein said sample preparation does not use primary amine buffers.

IPC Classes  ?

• C07C 233/12 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method of purifying peptides and/or polypeptides, said method comprising or consisting of: (a) loading a sample comprising peptides and/or polypeptides under acidic or neutral aqueous conditions on mixed-phase solid phase extraction (SPE) material, wherein said material consists of or comprises reversed phase/ion exchange material; (b) washing said mixed-phase SPE material with (ba) an acidic or neutral composition comprising at least 50% (v/v) organic solvent; and/or (bb) an acidic or neutral aqueous solution; and (c) eluting said peptides and/or polypeptides from said mixed-phase SPE material with an alkaline composition comprising at least 50% (v/v) organic solvent.

IPC Classes  ?

• C07K 1/16 - ExtractionSeparationPurification by chromatography

Abstract

A method of measuring a spectral response of a biological sample (1), comprises the steps generation of probe light having a primary spectrum, irradiation of the sample (1) with the probe light, including an interaction of the probe light and the sample (1), and spectrally resolved detection of the probe light having a modified spectrum, which deviates from the primary spectrum as a result of the interaction of the probe light and the sample (1), said modified spectrum being characteristic of the spectral response of the sample (1), wherein the probe light comprises probe light pulses (2) being generated with a fs laser source device (10). Furthermore, a spectroscopic measuring apparatus is described, which is configured for measuring a spectral response of a biological sample (1).

IPC Classes  ?

• G01N 21/03 - Cuvette constructions
• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis
• G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solidsPreparation of samples therefor
• G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
• G01N 21/3586 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation by Terahertz time domain spectroscopy [THz-TDS]
• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range

Abstract

The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

IPC Classes  ?

• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical

Abstract

The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/24 - Antidepressants
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

The silicon-based photomultiplier device comprises a substrate (1), a first layer (2) of a first conductivity type, a second layer (3) of a second conductivity type formed on the first layer, wherein the first layer (2) and the second layer (3) form a p-n junction, wherein the first layer (2) and the second layer (3) are disposed on or above the substrate (1). A material layer (15) between the substrate (1) and the first layer (2) fulfils the function of a light absorber, thereby efficiently suppressing crosstalk between adjacent cells of the device. Material layer (15) may further serve as an electrode for readout of electrical signals from the device.

IPC Classes  ?

• H01L 27/144 - Devices controlled by radiation
• H01L 31/0224 - Electrodes
• H01L 31/107 - Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier or surface barrier the potential barrier working in avalanche mode, e.g. avalanche photodiode

Abstract

In one aspect the application relates to a computing system for providing data for modelling a human brain comprises a database including a plurality of datasets (or allow access to a plurality of datasets), each dataset including at least a dynamical model of the brain including at least one node and a neurodataset of a neuroimaging modality input. The at least one node include a representation of a local dynamic model and a parameter set of the local dynamic model.

IPC Classes  ?

• G06N 3/00 - Computing arrangements based on biological models

Abstract

The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi- modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present invention refers to inhibitors of microRNAs, particularly of microRNAs miR-212 for use in medicine, particularly in the diagnosis, treatment or prevention of cardiac disorders, e.g. cardiac hypertrophy-associated or autophagic disorders, and further refers to isolated nucleic acid molecules, particularly microRNAs miR-212 and related sequences, for use in medicine, particularly human medicine, more particularly in the diagnosis, treatment or prevention of disorders involving cardiac atrophy and/or dysfunctional autophagy, e.g. cardiac cachexia.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention refers to inhibitors of microRNAs, particularly of microRNAs miR-212 and/or miR-132 for use in medicine, particularly in the diagnosis, treatment or prevention of cardiac disorders, e.g. cardiac hypertrophy-associated or autophagic disorders, and further refers to isolated nucleic acid molecules, particularly microRNAs miR-212 and/or miR-132 and related sequences, for use in medicine, particularly human medicine, more particularly in the diagnosis, treatment or prevention of disorders involving cardiac atrophy and/or dysfunctional autophagy, e.g. cardiac cachexia.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.

IPC Classes  ?

• A61K 38/13 - Cyclosporins
• A61P 31/12 - Antivirals
• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

For terminating a high frequency arrhythmic electric state of a biological tissue an electric signal representative of the present electric state of the biological tissue is obtained. From the electric signal a dominant frequency of the present electric state is determined, and from the dominant frequency it is determined whether the present electric state of the biological tissue is a high frequency arrhythmic electric state. Further, a dominance level indicative of how dominant the dominant frequency is in the high frequency arrhythmic electric state is determined from the electric signal. Depending on the at least one dominant frequency, at least one series of electric pulses at intervals is generated. The electric pulses are applied to the biological tissue starting at a point in time at which the dominance level exceeds a predefined threshold value for the biological tissue being in a determined high frequency arrhythmic electric state.

IPC Classes  ?

• A61N 1/362 - Heart stimulators
• A61N 1/37 - MonitoringProtecting

Abstract

The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 39/05 - CorynebacteriumPropionibacterium
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to a recombinant Mycobacterium cell for use as a vaccine.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.

IPC Classes  ?

• C12N 15/867 - Retroviral vectors

Abstract

The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other linRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively. The invention also relates to polypeptides, protein sets and antibodies that may be used in such methods and assays and for therapeutic use in RA and SLE patients.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids